Short Interest in PAVmed Inc. (NASDAQ:PAVM) Grows By 19.0%

PAVmed Inc. (NASDAQ:PAVM) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 293,400 shares, a growth of 19.0% from the August 15th total of 246,600 shares. Based on an average trading volume of 81,900 shares, the short-interest ratio is presently 3.6 days. Currently, 3.2% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their target price on shares of PAVmed from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, September 10th.

PAVmed Trading Down 3.6 %

Shares of NASDAQ:PAVM traded down $0.06 on Tuesday, reaching $1.71. 7,850 shares of the company’s stock were exchanged, compared to its average volume of 70,708. PAVmed has a twelve month low of $0.60 and a twelve month high of $5.70. The company has a fifty day moving average of $0.98 and a 200-day moving average of $1.48. The company has a market capitalization of $17.76 million, a price-to-earnings ratio of -0.19 and a beta of 0.66.

PAVmed (NASDAQ:PAVM) last issued its earnings results on Tuesday, August 13th. The company reported ($0.84) EPS for the quarter. The firm had revenue of $0.98 million for the quarter. As a group, equities research analysts forecast that PAVmed will post -5.88 EPS for the current fiscal year.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.